5-(3,3-Dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC, Fig. 1) was the first member of the series of antitumour triazenes and was chosen for clinical trial because of its activity against murine leukaemia L1210. Significant activity was demonstrated against malignant melanoma with an overall response rate of 21%, while marginal activity was demonstrated against other solid tumours.
KeywordsAntitumour Activity Human Leukaemia Cell Line Haemoglobin Synthesis Antitumour Agent L1210 Leukaemia Cell
Unable to display preview. Download preview PDF.
- 7.P.D. Lawley, DNA as a target of alkylating carcinogens, Brit. Med. Bull. 36:1 (1980).Google Scholar
- 14.J.A. Hickman, M.F.G. Stevens, N.W. Gibson, S.P. Langdon, C. Fizames, F. Lavelle, G. Atassi, E. Lunt and R.M. Tilson, Experimental antitumour activity against murine tumour model systems of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (Mitozolomide), a novel broad-spectrum agent. Cancer Res., 45:3008 (1985).PubMedGoogle Scholar
- 15.M.F.G. Stevens, J.A. Hickman, S.P. Langdon, D. Chubb, L. Vickers, R. Stone, G. Baig, C. Goddard, N.W. Gibson, J.A. Slack, C. Newton, E. Lunt, C. Fizames and F. Lavelle, Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M and B 39831), a novel drug with potential as an alternative to dacarbazine, Cancer Res. 47: 5846 (1987).PubMedGoogle Scholar
- 25.M.J. Tisdale, Antitumour Imidazotetrazinones — X. Effect of 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4-(3H)-one (CCRG 81045, M and B 39831, NSC 362856) on DNA methylation during induction of haemoglobin synthesis in human leukaemia cell line K562, Biochem. Pharmacol. 35:311 (1986).PubMedCrossRefGoogle Scholar
- 32.J. Vesley and A. Cihak, Incorporation of a potent antileukemic agent, 5-aza-2’-deoxycytidine into DNA of cells from leukemic mice, Cancer Res. 37:3684 (1977).Google Scholar